NCT03734029
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: HER2-low
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 3
Drug Category: Therapeutic Antibody, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with breast cancer that has ever expressed HER2+ and/or received anti-HER2 therapy; Patients with clinically active central nervous system metastases
https://ClinicalTrials.gov/show/NCT03734029